Candriam Luxembourg S.C.A. lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 538,948 shares of the biopharmaceutical company’s stock after selling 44,974 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Pfizer were worth $23,751,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Prio Wealth Limited Partnership raised its holdings in Pfizer by 3.2% during the 3rd quarter. Prio Wealth Limited Partnership now owns 1,039,655 shares of the biopharmaceutical company’s stock valued at $45,817,000 after buying an additional 32,071 shares during the period. Sterling Capital Management LLC raised its holdings in Pfizer by 16.6% during the 2nd quarter. Sterling Capital Management LLC now owns 2,478,848 shares of the biopharmaceutical company’s stock valued at $89,933,000 after buying an additional 353,212 shares during the period. Round Table Services LLC grew its position in Pfizer by 22.7% in the 3rd quarter. Round Table Services LLC now owns 19,327 shares of the biopharmaceutical company’s stock valued at $852,000 after acquiring an additional 3,580 shares during the last quarter. Essex Financial Services Inc. grew its position in Pfizer by 1.0% in the 2nd quarter. Essex Financial Services Inc. now owns 331,097 shares of the biopharmaceutical company’s stock valued at $12,012,000 after acquiring an additional 3,249 shares during the last quarter. Finally, R. G. Niederhoffer Capital Management Inc. bought a new position in Pfizer in the 2nd quarter valued at $512,000. Institutional investors own 70.61% of the company’s stock.
Pfizer stock opened at $41.70 on Thursday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer Inc. has a one year low of $34.32 and a one year high of $46.47. The stock has a market capitalization of $248.12 billion, a price-to-earnings ratio of 13.90, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77.
Pfizer announced that its Board of Directors has approved a stock repurchase plan on Friday, December 14th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to repurchase up to 3.8% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s management believes its shares are undervalued.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 1st. Stockholders of record on Friday, February 1st will be paid a $0.36 dividend. This represents a $1.44 annualized dividend and a dividend yield of 3.45%. This is a boost from Pfizer’s previous quarterly dividend of $0.34. The ex-dividend date is Thursday, January 31st. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.
In other news, EVP Douglas M. Lankler sold 38,800 shares of the firm’s stock in a transaction dated Wednesday, January 30th. The stock was sold at an average price of $41.19, for a total value of $1,598,172.00. Following the completion of the transaction, the executive vice president now directly owns 83,592 shares in the company, valued at $3,443,154.48. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Douglas M. Lankler sold 5,000 shares of the firm’s stock in a transaction dated Friday, February 1st. The stock was sold at an average price of $42.75, for a total value of $213,750.00. Following the completion of the transaction, the executive vice president now owns 83,592 shares of the company’s stock, valued at $3,573,558. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.
PFE has been the topic of several research analyst reports. ValuEngine downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $53.00 price objective on shares of Pfizer in a research report on Tuesday, December 11th. Atlantic Securities reaffirmed a “buy” rating and issued a $54.00 price objective on shares of Pfizer in a research report on Tuesday, November 27th. Credit Suisse Group reaffirmed a “neutral” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Thursday, December 20th. Finally, Barclays set a $40.00 price objective on Pfizer and gave the company a “neutral” rating in a research report on Friday, October 19th. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $44.68.
ILLEGAL ACTIVITY NOTICE: This article was reported by BBNS and is the sole property of of BBNS. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://baseballnewssource.com/2019/02/14/candriam-luxembourg-s-c-a-sells-44974-shares-of-pfizer-inc-pfe/3214885.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
See Also: What is a back-end load?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.